阿帕替尼对老年晚期非小细胞肺癌患者生命质量和免疫功能的影响

Effects of apatinib on quality of life and immune function in older adult patients with advanced non-small cell lung cancer

目的:分析阿帕替尼对老年晚期非小细胞肺癌患者生命质量和免疫功能的影响。方法:选取台州市肿瘤医院2017年1月至2021年1月收治的老年晚期非小细胞肺癌患者187例为研究对象,采用随机数字表法分为对照组93例、观察组94例。对照组采用卡铂联合培美曲塞治疗,观察组在对照组治疗的基础上联合阿帕替尼治疗。比较两组患者缓解情况、治疗前后肿瘤标志物水平、免疫功能、生命质量评分。结果:观察组总缓解率为88.30%,高于对照组的69.89%(χ^(2)=9.59,P<0.05)。治疗后,观察组糖类抗原125[(16.25±5.47)μg/L]、糖类抗原50[(15.23±3.27)μg/L]、癌胚抗原[(5.91±2.66)mg/L]均低于对照组[(21.49±6.61)μg/L、(19.11±3.48)μg/L、(10.14±2.73)mg/L],差异均有统计学意义(t=5.91、7.86、10.73,均P<0.001);观察组CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)分别为(69.34±8.85)%、(38.15±6.52)%、(1.40±0.33),均高于对照组的(64.51±8.74)%、(33.55±6.33)%、(1.23±0.25),差异均有统计学意义(t=-3.75、-5.36、-3.97,均P<0.001);两组生命质量评分均明显改善,且观察组改善程度均优于对照组(均P<0.001)。结论:阿帕替尼能有效改善老年晚期非小细胞肺癌患者的肿瘤标志物水平及免疫功能,提高其生命质量。

Objective:To analyze the effects of apatinib on quality of life and immune function in older adult patients with advanced non-small cell lung cancer.Methods:A total of 187 older adult patients with advanced non-small cell lung cancer admitted to Taizhou Cancer Hospital from January 2017 to January 2021 were included in this study.They were divided into the control group(n=93)and the observation group(n=94).The control group was treated with carboplatin combined with pemetrexed and the observation group was treated with apatinib based on carboplatin and pemetrexed.Sign and symptoms remission was compared between the observation and control groups.The levels of tumor markers,immune function,and quality of life score were compared between the two groups before and after treatment.Results:Total remission rate in the observation group was significantly higher than that in the control group(88.30%vs.69.89%,χ^(2)=9.59,P<0.05).After treatment,carbohydrate antigen 125,carbohydrate antigen 50,and carcinoembryonic antigen in the observation group were(16.25±5.47)μg/L,(15.23±3.27)μg/L and(5.91±2.66)mg/L,respectively,which were significantly lower than(21.49±6.61)μg/L,(19.11±3.48)μg/L and(10.14±2.73)mg/L in the control group(t=5.91,7.86,10.73,all P<0.05).The percentage of CD_(3)^(+)and CD_(4)^(+)cells,and the ratio of CD_(4)^(+)/CD_(8)^(+)cells in the observation group were(69.34±8.85)%,(38.15±6.52)%,(1.40±0.33),respectively,which were significantly higher than(64.51±8.74)%,(33.55±6.33)%,(1.23±0.25)in the control group(t=-3.75,-5.36,-3.97,all P<0.05).Quality of life score was increased in each group(P<0.001).The amplitude of increase in quality of life score was greater in the observation group compared with the control group(P<0.001).Conclusion:Apatinib can effectively reduce the level of tumor markers and improve immune function in older adult patients with advanced non-small cell lung cancer and improve quality of life.